Clinical Trials
12 trialsNCT01135329 2026-05-27
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT07359859 2026-05-27
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07524530 2026-05-27
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Not yet recruiting
NCT03434730 2026-05-26
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT07605364 2026-05-26
Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer
Alliance for Clinical Trials in Oncology
Phase 2/3 Not yet recruiting
NCT03246906 2026-05-14
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT04477200 2026-05-14
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
University of Michigan Rogel Cancer Center
Phase 1 Active not recruiting
NCT07566377 2026-05-14
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05088356 2026-05-12
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Stanford University
Phase 1 Active not recruiting
NCT06996119 2026-05-11
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT04888741 2026-05-05
MoTD
University of Birmingham
Phase 2 Recruiting
NCT03670966 2026-05-04
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting